Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

Oncogene

Volumn 25, Issue 2, 2006, Pages 304-309

  Bossi, G ^a   Lapi, E ^a   Strano, S ^a   Rinaldo, C ^a   Blandino, G ^a   Sacchi, A ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gain of function; Human cancer cells; Mutant p53; RNA interference

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CISPLATIN; COLONIC NEOPLASMS; COLONY-FORMING UNITS ASSAY; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; MICE; MICE, NUDE; MUTATION; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 30544452870     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209026     Document Type: Article

References (24)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. (1996). Nat Med 2: 811-814.
2. Blandino G, Levine AJ, Oren M. (1999). Oncogene 18: 477-485.
3. Brummelkamp TR, Bernards R, Agami R. (2002a). Cancer Cell 2(3): 243-247.
4. Brummelkamp TR, Bernards R, Agami R. (2002b). Science 296: 550-553.
5. Cadwell C, Zambetti GP. (2001). Gene 277(1-2): 15-30.
6. Care A, Felicetti F, Meccia E, Bottero L, Parenza M, Stoppacciaro A et al. (2001). Cancer Res 61(17): 6532-6539.
7. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M et al. (1993). Nat Genet 4(1): 42-46.
8. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. (1998). Mol Cell Biol 18: 3735-3743.
9. Irwin MS, Kondo K, Marin MC, Cheng CH, Kaelin WG. (2003). Cancer Cell 3: 403-410.
10. Lang GA, Iwakuma T, Suh YA, Liu G, Rao A, Parant JM et al. (2004). Cell 119: 861-872.
11. Lanyi A, Deb D, Seymour RC, Ludes-Meyers JH, Subler MA, Deb S. (1998). Oncogene 16: 3169-3176.
12. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R et al. (1998). Oncogene 16(25): 3269-3277.
13. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Cell 119: 847-860.
14. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al. (2001). J Biol Chem 276: 39359-39367.
15. Scian MJ, Stagliano KER, Deb D, Ellis MA, Carchman EV, Das A et al. (2004). Oncogene 23: 4430-4443.
16. Shaulian E, Zauberman A, Ginsberg D, Oren M. (1992). Mol Cell Biol 12: 5581-5592.
17. Shaulsky G, Goldfinger N, Rotter V. (1991). Cancer Res 51: 5232-5237.
18. Sigal A, Rotter V. (2000). Cancer Res 60: 6788-6793.
19. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L et al. (2000). J Biol Chem 275: 29503-29512.
20. Tsang WP, Ho FYF, Fung KP, Kong SK, Kwok TT. (2005). Int J Cancer 114: 331-336.
21. Vousden KH, Prives C. (2004). Cell 120: 7-10.
22. Wang LH, Okaichi K, Ihara M, Okumura Y. (1998). Anticancer Res 18: 321-325.
23. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M et al. (2004). Cancer Res 64(22): 8318-8327.
24. Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Concharov TM et al. (2003). Oncogene 22: 5667-5676.